• Edit Profile
  • Edit Consent
  • Sign Out
  • KEYTRUDA
    • WHAT IS KEYTRUDA
    • KEY TRIAL FACTS
    • HOW KEYTRUDA WORKS
    • TREATMENT OVERVIEW
    • IMPROVING ACCESS TO KEYTRUDA
    • REGISTERED INDICATIONS
    • CURRENT FUNDING
    • FAQs
  • INDICATIONS AND FUNDING
    • MELANOMA
    • LUNG CANCER
    • CLASSICAL HODGKIN LYMPHOMA
    • UROTHELIAL CANCER
    • HEAD AND NECK CANCER
    • IMPROVING ACCESS TO KEYTRUDA
  • EDUCATIONAL RESOURCES
    • HEALTHCARE PROFESSIONAL MATERIALS
      • HEALTHCARE PROFESSIONAL VIDEOS
      • MSD MANUALS AND UNIVADIS
    • PATIENT MATERIALS
  • TESTING
    • PD-L1 INHIBITION IN IO
    • MEASUREMENT OF PD-L1
    • REQUEST THE TEST
  • EVENTS
    • CTIO
    • NEWS AND UPDATES
  • CONTACT US
 

  • Terms of Use
  • Privacy Policy
  • Contact Us

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. NZ-KEY-00216 TAPS DA 2208KN Last updated January 2022.

Copyright © 2020-2022 Merck & Co., Inc., Kenilworth, NJ, USA, and its affiliates. All rights reserved.